| P50 | author | Peter Rieckmann | Q114301079 |
| | Massimo Filippi | Q48131182 |
| | Giancarlo Comi | Q66759549 |
| P2093 | author name string | Gianvito Martino | |
| | Jan Hillert | |
| | Luciano Adorini | |
| | Boris Kallmann | |
| P2860 | cites work | Induction and mechanism of action of transforming growth factor-beta-secreting Th3 regulatory cells | Q77291206 |
| | Myelin phagocytosis and remyelination of macrophage-enriched central nervous system aggregate cultures | Q77360098 |
| | Genetic basis for clinical expression in multiple sclerosis | Q77613127 |
| | Human antibodies accelerate the rate of remyelination following lysolecithin-induced demyelination in mice | Q77667922 |
| | HLA-DR15 and age at onset in multiple sclerosis | Q77737452 |
| | Familial factors influence disability in MS multiplex families. French Multiple Sclerosis Genetics Group | Q77759512 |
| | Therapeutic potential of TCR antagonists is determined by their ability to modulate a diverse repertoire of autoreactive T cells | Q77924855 |
| | APOE genotypes and disease severity in multiple sclerosis | Q78047087 |
| | Encephalitogenic potential of the myelin basic protein peptide (amino acids 83-99) in multiple sclerosis: results of a phase II clinical trial with an altered peptide ligand | Q73035541 |
| | Sex and age at diagnosis are correlated with the HLA-DR2, DQ6 haplotype in multiple sclerosis | Q73040182 |
| | Use of the brain parenchymal fraction to measure whole brain atrophy in relapsing-remitting MS. Multiple Sclerosis Collaborative Research Group | Q73187378 |
| | Thromboembolic complications after treatment with monoclonal antibody against CD40 ligand | Q73401367 |
| | Cytokine-induced modulation of cellular adhesion to human cerebral endothelial cells is mediated by soluble vascular cell adhesion molecule-1 | Q73585970 |
| | Autoimmune disease in first-degree relatives of patients with multiple sclerosis. A UK survey | Q73822014 |
| | Intrathecal delivery of IFN-gamma protects C57BL/6 mice from chronic-progressive experimental autoimmune encephalomyelitis by increasing apoptosis of central nervous system-infiltrating lymphocytes | Q74244362 |
| | Magnetization transfer ratios in multiple sclerosis lesions enhancing after different doses of gadolinium | Q74575044 |
| | Expression of specific chemokines and chemokine receptors in the central nervous system of multiple sclerosis patients | Q24563395 |
| | Multiple sclerosis: a modifying influence of HLA class I genes in an HLA class II associated autoimmune disease | Q28140475 |
| | Monoclonal antibody treatment exposes three mechanisms underlying the clinical course of multiple sclerosis | Q28144207 |
| | APOE genotype is a major predictor of long-term progression of disability in MS | Q28199870 |
| | Multiple sclerosis | Q28214785 |
| | Abnormal endothelial tight junctions in active lesions and normal-appearing white matter in multiple sclerosis | Q28215006 |
| | Association of polymorphisms in the apolipoprotein E region with susceptibility to and progression of multiple sclerosis | Q28218229 |
| | Regulation of immune responses by TGF-beta | Q28271433 |
| | Distinct patterns of multiple sclerosis pathology indicates heterogeneity on pathogenesis | Q28293364 |
| | Proinflammatory cytokines regulate antigen-independent T-cell activation by two separate calcium-signaling pathways in multiple sclerosis patients. | Q32091509 |
| | Correlations between monthly enhanced MRI lesion rate and changes in T2 lesion volume in multiple sclerosis. | Q32091527 |
| | Multiple sclerosis: histopathologic and MR and/or CT correlation in 37 cases at biopsy and three cases at autopsy | Q33648766 |
| | Gadolinium enhanced MRI predicts clinical and MRI disease activity in relapsing-remitting multiple sclerosis | Q33715006 |
| | A preliminary study into the sensitivity of disease activity detection by serial weekly magnetic resonance imaging in multiple sclerosis | Q33735120 |
| | Immunopathogenesis of multiple sclerosis: the role of T cells | Q33739582 |
| | Effector pathways in immune mediated central nervous system demyelination | Q33739587 |
| | Mechanisms of immunotherapeutic intervention by anti-CD40L (CD154) antibody in an animal model of multiple sclerosis | Q33835268 |
| | Disease activity in multiple sclerosis studied by weekly triple-dose magnetic resonance imaging | Q48128744 |
| | A longitudinal study of brain atrophy in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG). | Q48160545 |
| | Spatial mapping of T2 and gadolinium-enhancing T1 lesion volumes in multiple sclerosis: evidence for distinct mechanisms of lesion genesis? | Q48174546 |
| | Serial proton magnetic resonance spectroscopy in acute multiple sclerosis lesions | Q48182289 |
| | Clinical worsening in multiple sclerosis is associated with increased frequency and area of gadopentetate dimeglumine-enhancing magnetic resonance imaging lesions | Q48289106 |
| | Using gadolinium-enhanced magnetic resonance imaging lesions to monitor disease activity in multiple sclerosis | Q48399228 |
| | Serial proton magnetic resonance spectroscopic imaging, contrast-enhanced magnetic resonance imaging, and quantitative lesion volumetry in multiple sclerosis | Q48550799 |
| | Inflammatory central nervous system demyelination: correlation of magnetic resonance imaging findings with lesion pathology | Q48588737 |
| | T cell vaccination in multiple sclerosis: results of a preliminary study | Q48618101 |
| | Association of a null mutation in the CNTF gene with early onset of multiple sclerosis | Q48664430 |
| | Serial gadolinium-enhanced magnetic resonance imaging scans in patients with early, relapsing-remitting multiple sclerosis: Implications for clinical trials and natural history | Q48732448 |
| | TNF alpha promotes proliferation of oligodendrocyte progenitors and remyelination | Q48744723 |
| | Measurement of the blood-brain barrier permeability and leakage space using dynamic MR imaging. 1. Fundamental concepts | Q48797418 |
| | Increased MRI activity and immune activation in two multiple sclerosis patients treated with the monoclonal anti-tumor necrosis factor antibody cA2. | Q48851709 |
| | Elevated plasma endothelial microparticles in multiple sclerosis | Q48868741 |
| | Whole brain volume changes in patients with progressive MS treated with cladribine | Q49160798 |
| | Double-Blind Pilot Trial of Oral Tolerization with Myelin Antigens in Multiple Sclerosis | Q50127386 |
| | Blood-brain barrier disruption on contrast-enhanced MRI in patients with mild relapsing-remitting multiple sclerosis: relationship to course, gender, and age. | Q52510601 |
| | TNF is a potent anti-inflammatory cytokine in autoimmune-mediated demyelination. | Q54150165 |
| | No evidence to support CTLA-4 as a susceptibility gene in MS families: the Canadian Collaborative Study | Q56904649 |
| | HLA-DRB1 and disease outcome in multiple sclerosis | Q57306881 |
| | The Expression of Tissue-type Plasminogen Activator, Matrix Metalloproteases and Endogenous Inhibitors in the Central Nervous System in Multiple Sclerosis | Q57584744 |
| | Induction of a non-encephalitogenic type 2 T helper-cell autoimmune responsein multiple sclerosis after administration of an altered peptide ligand ina placebo-controlled, randomized phase II trial | Q57911995 |
| | Suggestive Evidence for Association of Human Chromosome 18q12-q21 and Its Orthologue on Rat and Mouse Chromosome 18 With Several Autoimmune Diseases | Q58201246 |
| | Linkage analysis in multiple sclerosis of chromosomal regions syntenic to experimental autoimmune disease loci | Q60057020 |
| | Pulsed monoclonal antibody treatment and autoimmune thyroid disease in multiple sclerosis | Q61651685 |
| | Oral tolerance to myelin basic protein and natural recovery from experimental autoimmune encephalomyelitis are associated with downregulation of inflammatory cytokines and differential upregulation of transforming growth factor beta, interleukin 4, | Q67543574 |
| | Anti-idiotypic network induced by T cell vaccination against experimental autoimmune encephalomyelitis | Q69014541 |
| | Tumor necrosis factor mediates myelin damage in organotypic cultures of nervous tissue | Q69049807 |
| | Tumor necrosis factor in serum and cerebrospinal fluid of patients with multiple sclerosis | Q69414426 |
| | Treatment of multiple sclerosis with T-cell receptor peptides: results of a double-blind pilot trial | Q71607051 |
| | The adhesion molecule and cytokine profile of multiple sclerosis lesions | Q71688111 |
| | Depletion of myelin-basic-protein autoreactive T cells by T-cell vaccination: pilot trial in multiple sclerosis | Q71710403 |
| | Control of established experimental allergic encephalomyelitis by inhibition of tumor necrosis factor (TNF) activity within the central nervous system using monoclonal antibodies and TNF receptor-immunoglobulin fusion proteins | Q72194401 |
| | Correlation between magnetic resonance imaging findings and lesion development in chronic, active multiple sclerosis | Q72605880 |
| | Magnetic resonance imaging of antibody-mediated demyelinating experimental allergic encephalomyelitis | Q72725602 |
| | Regulation of T-cell responses by CNS antigen-presenting cells: different roles for microglia and astrocytes | Q33846443 |
| | CTLA4Ig-mediated blockade of T-cell costimulation in patients with psoriasis vulgaris | Q33855058 |
| | Complexities of CD28/B7: CTLA-4 costimulatory pathways in autoimmunity and transplantation | Q34178136 |
| | The inflammation-induced pathological chaperones ACT and apo-E are necessary catalysts of Alzheimer amyloid formation | Q34469534 |
| | Autoimmune T cells protect neurons from secondary degeneration after central nervous system axotomy | Q34486849 |
| | CTLA-4 gene polymorphism may modulate disease in Japanese multiple sclerosis patients. | Q34505844 |
| | Pathogen-specific regulatory T cells provoke a shift in the Th1/Th2 paradigm in immunity to infectious diseases | Q34801855 |
| | Patterns of disease activity in multiple sclerosis: clinical and magnetic resonance imaging study | Q35168285 |
| | Gamma interferon activates a previously undescribed Ca2+ influx in T lymphocytes from patients with multiple sclerosis | Q35298405 |
| | Multiple sclerosis in sibling pairs: an analysis of 250 families | Q35464898 |
| | HLA-DR 15 is associated with female sex and younger age at diagnosis in multiple sclerosis. | Q35465548 |
| | Intracerebral recruitment and maturation of dendritic cells in the onset and progression of experimental autoimmune encephalomyelitis | Q35829642 |
| | Clustering of non-major histocompatibility complex susceptibility candidate loci in human autoimmune diseases | Q36282160 |
| | Expression of costimulatory molecules B7-1 (CD80), B7-2 (CD86), and interleukin 12 cytokine in multiple sclerosis lesions | Q36365596 |
| | CTLA-4: a negative regulator of autoimmune disease. | Q36367226 |
| | Uncoupling the proinflammatory from the immunosuppressive properties of tumor necrosis factor (TNF) at the p55 TNF receptor level: implications for pathogenesis and therapy of autoimmune demyelination | Q36376163 |
| | Myelin basic protein-specific T helper 2 (Th2) cells cause experimental autoimmune encephalomyelitis in immunodeficient hosts rather than protect them from the disease | Q36380402 |
| | Serial gadolinium enhanced magnetic resonance imaging in multiple sclerosis | Q36454469 |
| | Magnetic resonance imaging investigation of blood-brain barrier damage in adoptive transfer experimental autoimmune encephalomyelitis | Q36767941 |
| | Elevated interleukin-12 in progressive multiple sclerosis correlates with disease activity and is normalized by pulse cyclophosphamide therapy | Q37384434 |
| | HLA class II-associated genetic susceptibility in multiple sclerosis: a critical evaluation | Q37406401 |
| | Antigen analogs/MHC complexes as specific T cell receptor antagonists | Q40661137 |
| | Oral tolerance: immunologic mechanisms and treatment of animal and human organ-specific autoimmune diseases by oral administration of autoantigens | Q40661200 |
| | Patterns of blood-brain barrier breakdown in inflammatory demyelination | Q41186929 |
| | Evidence of linkage with HLA-DR in DRB1*15-negative families with multiple sclerosis | Q41816221 |
| | The capillaries in acute and subacute multiple sclerosis plaques: A morphometric analysis | Q42440923 |
| | Activated human T cells, B cells, and monocytes produce brain-derived neurotrophic factor in vitro and in inflammatory brain lesions: a neuroprotective role of inflammation? | Q42943930 |
| | Serum and CSF levels of MCP-1 and IP-10 in multiple sclerosis patients with acute and stable disease and undergoing immunomodulatory therapies | Q43562152 |
| | Production of MMPs in human cerebral endothelial cells and their role in shedding adhesion molecules | Q43577432 |
| | Heterogeneity of blood-brain barrier changes in multiple sclerosis: an MRI study with gadolinium-DTPA enhancement. | Q43611164 |
| | CTLA-4 gene expression is influenced by promoter and exon 1 polymorphisms | Q43653596 |
| | Macrophage depletion impairs oligodendrocyte remyelination following lysolecithin-induced demyelination | Q43700744 |
| | Duration and selectivity of blood-brain barrier breakdown in chronic relapsing experimental allergic encephalomyelitis studied by gadolinium-DTPA and protein markers | Q43726474 |
| | DQB1*0602 confers genetic susceptibility to multiple sclerosis in Afro-Brazilians | Q44494074 |
| | Human tumor necrosis factor-alpha augments experimental allergic encephalomyelitis in rats | Q46396148 |
| | Identification of autoantibodies associated with myelin damage in multiple sclerosis | Q46424597 |
| | Late complications of immune deviation therapy in a nonhuman primate | Q46594595 |
| | Phase 1 trial of transforming growth factor beta 2 in chronic progressive MS. | Q47801352 |
| | TGF-beta: a balancing act. | Q47912588 |
| | The CTLA-4 gene is associated with multiple sclerosis | Q47946644 |
| | Multisequence MRI in clinically isolated syndromes and the early development of MS. | Q48090149 |
| P433 | issue | 8 | |
| P921 | main subject | inflammation | Q101991 |
| | multiple sclerosis | Q8277 |
| P304 | page(s) | 499-509 | |
| P577 | publication date | 2002-12-01 | |
| P1433 | published in | Lancet Neurology | Q15755067 |
| P1476 | title | Inflammation in multiple sclerosis: the good, the bad, and the complex | |
| P478 | volume | 1 | |